At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 54 enrolled
Drug / intervention
GSK3888130B +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo Controlled, Single Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3888130B in Healthy Participants Aged 18-55 Inclusive
In Brief
A Phase 1 clinical trial evaluating GSK3888130B and Placebo for Multiple Sclerosis and Colitis, Ulcerative. Completed, enrolled 54 participants across 1 site.
Detailed Summary
This is a first time in human study designed to assess the safety, tolerability, pharmacokinetics and PD of GSK3888130B over a range of dose levels in healthy participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis, Colitis, Ulcerative
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
Enrollment StartNov 2021
First PostedNov 2021
Primary CompletionOct 2023
TodayJul 2026
First PostedNov 23, 2021
Enrollment StartNov 1, 2021
Primary CompletionOct 12, 2023
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 4.6 years ago
Interventions
GSK3888130Bdrug
GSK3888130B will be administered.
Placebodrug
Placebo will be administered.